Zurzuvae (zuranolone): state of practice

What zuranolone is and how it differs from brexanolone

Zuranolone is a neuroactive steroid, closely related to allopregnanolone, which is the endogenous progesterone metabolite that drops sharply after delivery. The pregnenolone-to-allopregnanolone system is one of the neurobiological levers under the postpartum depression hypothesis: the abrupt withdrawal of neurosteroid GABA modulation contributes to the depressive episode in vulnerable patients. Restoring GABA-A tone quickly, the theory goes, corrects the acute imbalance and lets the system reset.

The brexanolone story is the same drug's older sibling. Brexanolone (Zulresso, approved 2019) is IV allopregnanolone, given as a 60-hour continuous infusion in a monitored setting with a REMS program. It's effective, but the logistics (60 hours of hospitalization or infusion center, driving restriction, specialized supervision) made it unusable outside a handful of centers. Zuranolone is the oral, at-home version of the same idea: a 14-day pill course covering the same neurochemical territory, without the hospitalization requirement.

Structurally, zuranolone is a synthetic allopregnanolone analogue with better oral bioavailability and a half-life around 20 hours. It hits both synaptic and extrasynaptic GABA-A receptors, whereas benzodiazepines primarily hit synaptic sites. That distinction matters because extrasynaptic GABA-A receptors mediate tonic inhibition and are thought to be more relevant to sustained mood regulation. It's the reason zuranolone isn't just a benzo dressed up in a new indication.

What the trials showed

The pivotal PPD trials are ROBIN and SKYLARK. Both are 14-day treatment periods with follow-up out to day 45.

ROBIN (Deligiannidis et al., JAMA Psychiatry 2021) tested 30 mg zuranolone in 151 women with severe PPD. HAMD-17 separation from placebo was 4.2 points at day 15, and the effect was maintained at day 45.

SKYLARK (Deligiannidis et al., Am J Psychiatry 2023) tested the FDA-approved 50 mg dose in 196 women. HAMD-17 separation was 4.0 points at day 15, statistically significant with sustained effect through day 45. Response (50 percent HAMD reduction) at day 15 was 57 percent for zuranolone versus 39 percent for placebo. Remission (HAMD-17 at or below 7) was 44 percent versus 29 percent. The kinetics of response are fast: HAMD separation from placebo appeared by day 3 in both trials, which is unlike anything the SSRI/SNRI class produces.

The non-PPD MDD program is worth mentioning because it shapes prescribing expectations. Two large trials (MOUNTAIN, WATERFALL) in general major depressive disorder had mixed results. Zuranolone showed some benefit at earlier timepoints but did not consistently separate from placebo on the primary endpoints. The FDA declined to approve zuranolone for MDD in 2023. This is not a general antidepressant. The approval is specifically for postpartum depression, and the label carries no MDD claim.

Dosing, timing, and food

The 14-day course is fixed. Fifty milligrams once daily in the evening, taken with a fat-containing food (about 400 to 1,000 kcal, with 25 to 50 percent fat) to make absorption reliable. Bioavailability without food is roughly half what it is with a fatty meal, which is a meaningful difference.

Bedtime dosing is not accidental. The sedation is dose-limiting, and dosing at bedtime lets the patient sleep through the peak. Instructing the patient to take it with dinner or with an evening snack that includes fat (peanut butter, cheese, a real meal with oil) and to be in bed within the hour is the practical framing.

The full course must be completed even if the patient feels better on day 5 or 7. The trials showed sustained effect through day 45 following the 14-day course, and that finding assumes the full course was delivered. Stopping early after early response is off-label and unstudied. If side effects at 50 mg are intolerable, the label allows dose reduction to 40 mg. Below that, there's no approved regimen. Discontinuation because of intolerability rather than dose reduction happened in about 5 percent of trial patients.

Sedation, driving, and functional restriction

The label carries a boxed warning for effect on driving and mental function. Following each 50 mg dose, patients cannot drive or engage in activities requiring full alertness for at least 12 hours. That's a real logistical problem in postpartum care because the patient often has an infant to feed at night and a family that expects her to function during the day. Practical framing that helps:

Take the dose at bedtime after the last feed, so the peak sedation happens during infant sleep hours rather than during the patient's own most alert window. Arrange for a partner, family member, or postpartum doula to handle the middle-of-the-night infant care during the 14 days if possible. Do not drive during the 14 days unless the appointment is more than 12 hours after the last dose and the patient feels fully alert. Plan pediatrician visits and errands around a driver.

The 12-hour restriction is the most common reason patients decline the drug. If the family structure can't absorb it, another option (SSRI, IPT, brexanolone at a center that provides it) may be more realistic.

Other common adverse events in the trials: somnolence (36 percent), dizziness (13 percent), fatigue (10 percent), diarrhea, sedation. Most are dose-related and taper off after the course ends. Serious adverse events including one suicidal ideation event in the pooled trials led the FDA to include boxed warning language about worsening depression and suicidal ideation, consistent with the class-wide antidepressant warning.

Schedule IV and prescribing logistics

Zuranolone is DEA Schedule IV because of the GABA-A mechanism. That means: no refills without a new prescription, controlled substance record-keeping, and in some states additional PDMP query and paper-prescription requirements. The 14-day course is dispensed as a single fill, which simplifies the schedule issue but means the patient can't restart mid-course if a bottle is lost or damaged.

The specialty pharmacy path is standard. Sage Therapeutics (developer, in partnership with Biogen) uses a limited distribution model. Prescriptions typically route through a specific specialty pharmacy which coordinates prior authorization, patient assistance, and shipping. Turnaround time from prescription to receiving the medication is typically 3 to 7 days.

Prior authorization is nearly universal in commercial insurance. Documentation that helps:

• PPD onset within the postpartum period (usually within 12 months of delivery, though the label doesn't specify a strict cutoff)
• HAMD-17 or PHQ-9 score consistent with moderate to severe depression
• Whether the patient has tried an SSRI/SNRI and either failed or wanted a faster-acting option
• Rationale for zuranolone specifically over an SSRI (speed of response, patient preference, breastfeeding considerations if relevant)

Breastfeeding

The label recommends that a lactating patient consider not breastfeeding during the 14-day course and for one week after the last dose. Zuranolone and its metabolites are found in breast milk in small amounts, and the effect on the breastfed infant is unknown.

The clinical practice around this is not settled. Some patients pump and discard through the treatment window and use previously stored milk or formula. Some patients elect to briefly discontinue breastfeeding and resume after the washout. Some patients accept the theoretical risk and continue breastfeeding, arguing that the actual measured infant exposure is very low and that active PPD is itself a substantial infant risk. The label recommendation is what it is, and the informed conversation with the patient should include what her breastfeeding goals are, whether pumping and storing is feasible, and how the family will handle the interruption.

Brexanolone, notably, does not carry the same breastfeeding recommendation, and that difference in labeling is one reason some centers still infuse brexanolone for lactating patients who cannot accept the zuranolone breastfeeding restriction. Both drugs are neurosteroids, and the differences in the labels reflect the trial designs more than a real pharmacologic difference in infant exposure.

Where zuranolone fits right now

The clinical role in mid-2026 is clearer than it was in 2023. Three patient scenarios come up:

The first is moderate to severe PPD where the patient needs rapid symptom relief and can absorb the 14-day driving restriction. This is the strongest use case. She gets relief in days rather than weeks, doesn't need to be on daily medication for six months, and has a defined endpoint. The family structure has to support the sedation window.

The second is patients who've had prior antidepressant trials with delayed response or intolerable side effects and are approaching a new pregnancy or postpartum period. Zuranolone gives them a plan that isn't "wait six weeks on sertraline again."

The third is patients where breastfeeding is the top priority and cannot be interrupted. Here zuranolone is often not the right fit, and sertraline or paroxetine (both well-studied in lactation) become first-line, with brexanolone as a second-line option at centers that offer it.

What zuranolone is not: it is not for general MDD (FDA did not approve that indication, and off-label use here is prescribing outside the evidence). It is not maintenance therapy. It is not for anxiety disorders. It is not for bipolar depression (the trials excluded bipolar patients, and the GABA mechanism carries theoretical activation risk that has not been characterized).

Cost and access

List price is around $16,000 for the 14-day course, which is far more than a year of generic sertraline but bounded (single fill, no ongoing cost). Insurance coverage as of mid-2026 has broadened. Most Medicaid programs cover it with prior authorization requiring PPD diagnosis and often a documented recent HAMD or PHQ-9 score. Commercial coverage is common with the same PA requirement. Copay assistance through the manufacturer brings the out-of-pocket for commercially insured patients to a small amount, and there's a patient assistance program for uninsured patients.

The specialty pharmacy path means the patient does not pick this up at a Walgreens. Setting the expectation that the medication ships to the home in a few days after the PA clears helps.

Common questions

Can zuranolone be combined with an SSRI? Sometimes. The trials allowed patients on stable SSRIs to receive zuranolone, and the response wasn't obviously worse. For a patient already on sertraline who's still symptomatic, adding zuranolone as a 14-day course is a legitimate strategy, and the SSRI provides ongoing maintenance after the zuranolone finishes. Watch for additive sedation and the same driving restriction. Serotonergic combinations don't apply here (zuranolone isn't serotonergic).

What happens if depression comes back after the 14 days? The trial follow-up went to day 45 and showed sustained effect for most responders. Relapse after that has not been rigorously studied. In practice, if depression returns, the options are: reintroduce an SSRI for maintenance (which many patients will already have been on), consider a second zuranolone course (off-label, unstudied, but sometimes done), or add psychotherapy focused on postpartum period. There's no established rule about repeat courses.

Is zuranolone addictive? The pharmacology is GABA-A modulation, which shares mechanism space with benzodiazepines and alcohol. The 14-day fixed course limits exposure and there's no evidence of withdrawal or dependence in the trials. It's Schedule IV because the mechanism carries theoretical abuse liability, not because clinical data shows it. Long-term or repeated use has not been characterized, so the question stays open for now.

Can zuranolone be used before delivery? Not for PPD (the drug is postpartum-indicated) and not studied in pregnancy. Animal reproductive toxicity data showed developmental effects at doses higher than human exposure. The label recommends against pregnancy exposure. For a patient with severe antepartum depression, the standard options remain sertraline, escitalopram, or a discussion with maternal-fetal medicine.

How does zuranolone compare to brexanolone? Same neurosteroid mechanism, same effect size in trials. Brexanolone is IV infusion over 60 hours at a monitored setting; zuranolone is oral at home for 14 days. Brexanolone works faster (effect appearing in 24 hours) but the 60-hour hospitalization is a major barrier. Zuranolone is more scalable but has the driving restriction and the breastfeeding label. For most patients, zuranolone is the more practical option. Brexanolone still has a role for patients who cannot organize the 12-hour daily driving restriction or who need faster onset than day 3.

What about anxiety symptoms? PPD often includes prominent anxiety symptoms. In the SKYLARK trial, the anxiety-related HAMD items improved along with the depression items, and the GAD-7 also improved. Zuranolone is not specifically approved for postpartum anxiety, but the clinical experience is that anxiety symptoms tend to improve when the depression improves. For pure postpartum anxiety without depression, the evidence base is thinner and SSRIs or short-term hydroxyzine are more standard.

Is monitoring needed during the 14 days? Standard suicide risk assessment applies. A check-in call or visit around day 5 to 7 is reasonable practice, both to catch adverse events early and to reinforce the driving restriction. No specific labs are required. If a patient is on a QT-prolonging medication, standard ECG monitoring for the other medication applies, but zuranolone itself has not been associated with QT prolongation.

What's next

The unmet need in PPD is much larger than the current zuranolone use suggests. Screening rates for PPD have improved but still miss a large fraction of cases, and treatment access lags screening. Zuranolone is a genuine addition to the toolkit for the right patient, but it's not a public health solution to postpartum depression. It's a treatment option that requires a diagnosis, an insurance path, a family structure, and a prescriber comfortable with the schedule and the boxed warning.

The neurosteroid class has several other compounds in development for MDD, PPD, and treatment-resistant depression. If any of them succeed in general MDD (which zuranolone did not), the class becomes a much bigger story. For now, zuranolone stays a specialty tool for a specific indication.

Sources

• Deligiannidis KM, Meltzer-Brody S, Gunduz-Bruce H, et al. Effect of zuranolone vs placebo in postpartum depression: a randomized clinical trial. JAMA Psychiatry. 2021;78(9):951-959.
• Deligiannidis KM, Meltzer-Brody S, Maximos B, et al. Zuranolone for the treatment of postpartum depression: SKYLARK. Am J Psychiatry. 2023;180(9):668-675.
• Zurzuvae (zuranolone) capsules, for oral use. Prescribing information. Sage Therapeutics and Biogen; approved August 4, 2023. Available via DailyMed.
• Kanes S, Colquhoun H, Gunduz-Bruce H, et al. Brexanolone (SAGE-547 injection) in post-partum depression. Lancet. 2017;390(10093):480-489.
• ACOG Committee Opinion No. 757: Screening for perinatal depression. Obstet Gynecol. 2018;132(5):e208-e212.